Cognition Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Cognition Therapeutics, Inc. (CGTX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $349.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-26.
Discontinued › Notes
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-03-26
- Cognition Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $160.00K.
- Cognition Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $349.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|
| 2022-12-31 | $160.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $349.00K 10-K · filed 2024-03-26 | |
| 2022-09-30 | $189.00K 10-Q · filed 2023-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |